This site is a comprehensive resource for biotech enthusiasts, including investors, researchers, media, etc. You'll find information about drug discovery and development, the FDA approval process, and loads of links and information about specific drugs and biotech companies.
BiotechDueDiligence's Latest Posts
Enjoy the following collection of OPEN ACCESS journal articles from the world of cancer research and development. MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung Schildhaus et al. Clinical Cancer Research. $ARQL ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice Regina et al. Molecular Cancer Therapeutics. (Angiochem) High HER2 Expression Correlates with Response to […]
Another fast-paced week on the biotech Twitter stream. Catch up on all the highlights with the latest edition of the Biotech Tweets of the Week. Thanks as always to @23aloha for collecting most of these! [...]
It may be too cold for school today around here, but the latest Biotech Tweets of the Week are live. The collection was curated as always with @23aloha. [...]
It is out turn to watch the snow fall here in the DC area. Best wishes for this winter weekend, wherever you are. Enjoy the latest collection of reading from around the web for the biotechnology / pharma / drug development enthusiast.Does a Real Anti-Aging Pill Already Exist?Bill Gifford (Bloomberg BusinessWeek)Rapamycin And Aging: The Spotlight ShinesDerek Lowe (In the Pipeline)Can This Treatment Help Me? There’s a Statistic for ThatAustin Frakt and Aaron Carroll (The Upshot / New York […]
Hard to believe it has been a month since FMI stockholders woke up to the tremendous deal news with Roche. Hopefully it won't jinx the ongoing tender/vote process but I have been meaning to post some highlights of the coverage.Genentech Redux? Roche Buys Majority Stake in Foundation MedicineBen Fidler (Xconomy)Roche Spends $1.03 Billion For Majority Stake In Foundation MedicineMatthew Herper (Forbes)It Had to be You: Why Roche Was The Lone Suitor For FoundationSteve Dickman (Xconomy)I […]
Log in to leave a comment